PC
BMRN icon

PA Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

PA Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-5,806
Closed -$491K – 167
2019
Q4 		$491K Buy
5,806
+285
+5% +$21.5K 0.43% 86
2019
Q3 		$372K Buy
5,521
+2,598
+89% +$200K 0.37% 91
2019
Q2 		$250K Sell
2,923
-328
-10% -$28.1K 0.23% 91
2019
Q1 		$289K Sell
3,251
-2,376
-42% -$220K 0.26% 91
2018
Q4 		$479K Buy
+5,627
New +$535K 0.51% 67

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PA Capital's BMRN Position: Q1 2020 in Review

PA Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2020, closing a stake of 5,806 shares — an estimated $491K sold.

PA Capital first reported a position in BMRN in Q4 2018 and held it in 5 quarters. The position peaked at $491K in Q4 2019. 500 funds tracked by Wall St. Rank hold BMRN as of Q1 2020.

  • PA Capital reported no remaining BioMarin Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • PA Capital sold 5,806 BioMarin Pharmaceuticals shares in Q1 2020, an estimated $491K.
  • PA Capital first reported a position in BioMarin Pharmaceuticals in Q4 2018 and held it in 5 quarters.
  • PA Capital's BioMarin Pharmaceuticals position peaked at $491K in Q4 2019.
  • 500 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2020.

Based on PA Capital's 13F filing for Q1 2020, filed 11 May 2020.